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Abstract
Background: Reduced bone mineral density (BMD) and osteoporosis are frequent in Crohn's
disease (CD), but the underlying mechanisms are still not fully understood. Deficiency of sex
steroids, especially estradiol (E2), is an established risk factor in postmenopausal osteoporosis.
Aim: To assess if hormonal deficiencies in male CD patients are frequent we investigated both,
sex steroids, bone density and bone metabolism markers.
Methods: 111 male CD patients underwent osteodensitometry (DXA) of the spine (L1–L4).
Disease related data were recorded. Disease activity was estimated using Crohn's disease activity
index (CDAI). Testosterone (T), dihydrotestosterone (DHT), estradiol (E2), sex hormone binding
globulin (SHBG), Osteocalcin and carboxyterminal cross-linked telopeptids (ICTP) were measured
in 111 patients and 99 age-matched controls.
Results: Patients had lower T, E2 and SHBG serum levels (p < 0.001) compared to age-matched
controls. E2 deficiency was seen in 30 (27.0%) and T deficiency in 3 (2.7%) patients but only in 5
(5.1%) and 1 (1%) controls. Patients with E2 deficiency had significantly decreased T and DHT
serum levels. Use of corticosteroids for 3 of 12 months was associated with lower E2 levels (p <
0.05). Patients with life-time steroids >10 g had lower BMD. 32 (28.8%) patients showed
osteoporosis, 55 (49.5%) osteopenia and 24 (21.6%) had normal BMD. Patients with normal or
decreased BMD showed no significant difference in their hormonal status. No correlation between
markers of bone turnover and sex steroids could be found. ICTP was increased in CD patients (p
< 0.001), and patients with osteoporosis had higher ICTP levels than those with normal BMD.
Conclusion: We found an altered hormonal status – i.e. E2 and, to a lesser extent T deficiency –
in male CD patients but failed to show an association to bone density or markers of bone turnover.
The role of E2 in the negative skeletal balance in males with CD, analogous to E2 deficiency in
postmenopausal females, deserves further attention.
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Background
Osteopenia and osteoporosis are frequently seen in
Crohn's disease (CD) [1-7]. The prevalence of oste-
oporotic fractures is strikingly high, both in females and
males [1,2,8-11]. However, pathogenesis and the risk fac-
tors indicative of an altered bone homeostasis are not
fully understood. Most studies suggest a major impact of
corticosteroid (CS) treatment on bone mineral density
(BMD) but inflammation per se may exert an important
risk since key inflammatory mediators such as the pro-
inflammatory cytokines tumour necrosis factor-alpha
(TNF-alpha), interleukin-1 beta (IL-1 beta) or IL-6 and
other TNF-related cytokines such as receptor activator of
nuclear factor kappa B (RANK) and its ligand, RANKL or
osteoprotegerin are directly involved in the disease proc-
ess [3,5-7,9,12-14].
In postmenopausal osteoporosis, the importance of sex
steroid deficiency, especially estradiol (E2) deficiency, is
well established [15-18]. Women with CD are at an
increased risk of amenorrhoea and premature menopause
[1]. Hormone replacement therapy (HRT) has been
shown to be an effective treatment to prevent bone loss in
postmenopausal women with CD [19].
Osteoporosis is often considered to be a disease of
women, men lose half as much bone with aging and have
one third as many fragility fractures as do women [15].
The regulation of bone metabolism involves a complex
interplay between different factors, including sex steroids
[15,17,18,20,21]. As of today, little is known about the
prevalence of sex steroid deficiency in male CD patients
and its contribution to bone loss and osteoporosis.
Previous studies investigating testosterone (T) and the
gonadotropins follicle stimulating hormone (FSH) and
luteinizing hormone (LH), reported lower than normal T
levels in 4/48 (8%) male CD patients with the free andro-
gen index (FAI) low in three patients and normal gonado-
tropins [22]. T was positively associated with osteocalcin
[22]. Others report T deficiency in 20/45 (44.4%) male
IBD patients but no effect on bone density and metabo-
lism was detected [23]. Lower than normal dehydroepian-
drosterone sulfate (DHEAS) levels have been found in
IBD patients, in part dependent on previous glucocorti-
coid treatment [24,25]. High cortisol and low DHEAS lev-
els were associated with higher humoral inflammatory
activity, and vice versa [24]. Lower levels of DHEAS
plasma levels in male IBD patients were associated with
lower BMD and with higher deoxypyridinoline excretion.
DHEAS correlated with BMD at the lumbar spine and
femoral neck [23].
There are no data about estrogen (E), estradiol (E2) or the
free estrogen index (FEI) and its association to bone loss
and osteoporosis in men with CD.
Because E and T are the major sex steroids both in
women and men, respectively, E was suggested to regu-
late bone turnover in women and T in men [20]. Loss
of E after menopause is the single most important
factor in development of postmenopausal bone loss
and osteoporosis [15,18,21]. There is also growing evi-
dence of a major role of estrogens in the regulation of
bone metabolism in men [15,17,20,21,26]. Male
patients with E resistance due to an oestrogen receptor
missense mutation [27] or aromatase deficiency associ-
ated failure to convert androgens to estrogens [28,29]
showed that E is important for optimal bone mass
acquisition in young adulthood and for the retardation
of bone loss in aging individuals [20]. Therefore,
declining levels of E, especially estradiol (E2), may con-
tribute to age-related bone loss in men suggesting that
the male skeleton may require a threshold level of E for
preventing increased bone resorption and bone loss
[15,18,20,21,26,30,31].
Hormonal changes, especially altered E2 status, may
therefore be a relevant factor for bone loss and osteoporo-
sis in male patients with inflammatory bowel disease
(IBD).
To assess if hormonal deficiencies in male CD patients are
frequent and to address the role of these hormonal
changes as relevant factor for bone loss and osteoporosis
we investigated sex steroid serum levels, including E2, in
111 male CD patients and 99 age-matched male controls.
In the 111 male CD patients, sex steroid serum levels were
related to bone density and metabolism.
Materials and methods
Patients
111 consecutive male CD outpatients were included in
the study. All patients had a prior diagnosis of Crohn's
disease based on histological, endoscopic, radiological or
clinical criteria. Disease related data on the previous and
current state of health were recorded using a standardised
questionnaire. Disease activity was estimated using the
Crohn's disease activity index (CDAI) [32]. Nutritional
status was assessed by body mass index (BMI). Cumula-
tive life-time steroid dose was estimated and expressed in
grams of prednisolone equivalent. Current CS use was
defined as patients who have used CS for at least 3 of the
past 12 months and patients who used CS at the date of
the study.
Exclusion criteria included: (1) age less than 18 years,
(2) chronic renal insufficiency (serum creatinine >1.5
mg/dl), (3) known primary hypo- or hyperparathy-
roidism, (4) untreated thyroid disease, (5) Paget's dis-
ease of bone, and any known medication or condition
affecting bone density or sex hormone status other than
glucocorticoids.BMC Gastroenterology 2008, 8:48 http://www.biomedcentral.com/1471-230X/8/48
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Controls
The 99 age-matched male controls were recruited from
healthy blood-donors who were not on medication or suf-
fering from any known condition affecting bone density
or sex hormone status.
Ethical consideration
The study was approved by the Ethics Committee of the
University of Ulm, Germany, (application number
1282000), and conducted in accordance with the 1975
Helsinki Declaration, as revised in 1983. All participants
gave oral and written informed consent before inclusion.
Laboratory testing
Blood samples were obtained in the morning, frozen and
stored at -70°C until assayed. The sex hormone status was
established in all subjects by measuring total testosterone
[T; DSL-4000 ACTIVE™ Testosterone Radioimmunoassay,
DSL GmbH Germany; intra- and interassay coefficients of
variation (CVs) were 7.8–9.6% and 8.4–9.1%, respec-
tively, sensitivity was 0.28 nmol/l, normal range: 9.7–30.5
ng/ml], dihydrotestosterone (DHT; DSL-9600 ACTIVE™
Radioimmunoassay, DSL GmbH Germany; CVs were 3.1–
6.2% and 2.3–8.5%, respectively, sensitivity was 4.0 pg/
ml, normal range: 94 – 476 pg/ml), estradiol (E2; DSL-
39100 Radioimmunoassay, DSL GmbH Germany; CVs
were 3.4–3.9% and 4.1–9.9%, respectively, sensitivity was
0.6 pg/ml, normal range: 21 – 41 pg/ml) and sex hor-
mone binding globulin, the major high affinity sex ster-
oids binding transport protein (SHBG; KP32CT
Radioimmunoassay, DSL GmbH Germany; CVs were 4.2–
5.9% and 4.6–5.9%, respectively, sensitivity was 2.5
nmol/ml, normal range 9 – 55 nmol/ml). The free andro-
gen (FAI, testosterone/SHBG × 100) and estrogen (FEI,
estradiol/SHBG × 100) index were calculated to estimate
the bioavailable amount of T and E2. Serum osteocalcin
(DSL-7600 ACTIVE™ Radioimmunoassay, DSL GmbH
Germany; CVs were 1.4–4.6% and 3.2–5.8%, respectively,
sensitivity was 0.3 ng/ml) and ICTP (ICTP Radioimmu-
noassay, Orion Diagnostica; CVs were 2.8–6.2% and 4.1–
7.9%, respectively, sensitivity was 0.5 μg/ml, normal
range: 1.3–5.2) were measured as markers of bone turno-
ver, indicating bone formation and resorption. Normal
reference ranges were provided by the manufacturers.
Measurement of bone mineral density
Bone mineral density (BMD) of the lumbar spine (L1–L4)
was assessed by DXA (Hologic QDR 1000, Hologic Inc.,
Waltham, MA). The average BMD values for L1–L4 were
used for calculations. Normal values were supplied by
Hologic Inc.. Assessment of BMD was performed accord-
ing to the manufacturer's instructions. Bone mineral den-
sity (BMD) results were expressed as number of standard
deviations (SD) from the peak bone mass of a young adult
gender-matched reference population (T-score). Accord-
ing to WHO recommendation for postmenopausal
women, osteopenia was defined as T-score < -1.0 SD, oste-
oporosis as T-score < -2.5 SD [33].
Statistics
Results are given as median and range since data were not
normally distributed. Qualitative variables are expressed
as frequency (n) and percentage (%). For comparison of
group means, the Mann Whitney non parametric rank test
was used. Two-tailed tests for significance were used in all
statistical analyses and p = 0.05 was considered statisti-
cally significant. Correlation coefficients were calculated
by using Spearman's rank correlation test. Stepwise linear
regression analysis was used to determine independent
variables predictive for BMD. The Statistical Package SAS
V6.11 was used for the analysis.
Results
• Baseline clinical characteristics
111 male CD patients were included in this study and
compared to 99 age-matched healthy male controls. Table
1 provides baseline characteristics.
￿ Biochemical markers – Sex steroid serum levels
Compared to age matched controls, patients had signifi-
cantly decreased serum levels of testosterone (T, 18.2
nmol/l vs. 21.4 nmol/l), estradiol (E2, 25.6 pg/ml vs. 33.7
pg/ml, see figure 1) and sex hormone binding globulin
(SHBG, 21.0 nmol/l vs. 33.2 nmo/l; p < 0.001 each) (table
2). No significant difference could be observed comparing
dihydrotestosterone (DHT) serum levels and the free
estrogen index (FEI). The free androgen index (FAI) was
higher in patients (87 vs. 65; p < 0.01) but 6 patients (two
patients with osteoporosis) and only 2 controls had a FAI
< 30. T deficiency (< 9.7 nmol/l) but normal FAI was seen
in 3 (2.7%) patients and 1 control, with 2 of these 3
patients suffering from osteoporosis.
E2 serum levels below the normal range (< 21 pg/ml)
were seen in 30 (27.0%) patients including 14 patients
with osteoporosis but in only 5 (5.1%) controls. Patients
with E2 deficiency had significantly lower serum levels of
T, DHT, FAI and FEI and a higher disease activity (CDAI)
compared to patients with normal E2 serum levels (table
3).
Patients with a regimen including CS for at least 3 of the
past 12 months before the study had lower E2 (24.7 pg/
ml vs. 26.7 pg/ml; p < 0.05) and T (16.1 nmol/l vs. 20.6
nmol/l; p < 0.01) serum levels compared to patients who
had not used CS. The difference in E2 and T serum levels
of current CS users and CS non-users did not reach statis-
tical significance.BMC Gastroenterology 2008, 8:48 http://www.biomedcentral.com/1471-230X/8/48
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With age, T and FAI decreased in both, patients (T: r = -
0.24, p < 0.01; FAI: r = -0.27, p < 0.01) and controls (FAI:
r = -0.34, p < 0.001), while SHBG serum levels increased.
E2 and FEI decreased in controls but not in patients (r = -
0.33, p < 0.001 and r = -0.28, p < 0.001, respectively), but
patients had lower E2 levels in all groups of age (table 4).
Patients with active (CDAI > 150) compared to non-active
disease (CDAI < 150) had significantly lower FEI (40 vs.
50; p < 0.025). Higher BMI was associated with higher E2
and FEI levels (table 5).
￿ Bone mineral density
The mean lumbar BMD T-score of the 111 CD patients
was -1.98 ± 1.06. 32 patients (28.8%) showed osteoporo-
sis, 55 (49.5%) osteopenia and 24 (21.6%) patients had
normal lumbar BMD (table 6).
Patients with a life-time steroid dose >10 g had a lower
lumbar BMD (T-score -2.39 ± 1.03 vs. -1.71 ± 0.98, p <
0.005). BMD and BMI were interrelated, patients with the
lowest BMI < 20 having the lowest BMD (table 5). BMD
decreased with age in CD patients (table 4).
In the linear regression analysis, the only significant inde-
pendent predictors for BMD of the lumbar spine were age
(p = 0.04), BMI (p = 0.002) and life-time steroid dose > 10
g (p = 0.007). These variables together accounted for 19%
of BMD T-score.
￿ Biochemical markers – Sex steroids and bone mineral 
density
No significant differences in the sex steroid serum levels
could be detected comparing the sub-groups of patients
with normal lumbar BMD, osteopenia or osteoporosis,
respectively (table 6) and no difference in lumbar BMD of
patients with vs. without E2 deficiency was seen (table 3).
Table 1: Baseline characteristics
Patients Controls
Number n = 111 n = 99
Age (yr) 35 (19 – 71) 38 (22 – 68)
Body mass index (kg/m2) 23.4 (16.8 – 34.7) n.a.
T-score lumbar spine -1.98 (-3.94 – 0.84) n.a.
Patients with osteopenia
(-2.5 T-score < -1)
55/49.6% n.a.
Patients with osteoporosis
(T-score < -2.5)
32/28.8% n.a.
CDAI 104 (2 – 380) n.a.
Duration of disease (yr) 8 (0.1 – 41.2) n.a.
Maximal digestive extension:
- small inflammatory bowel disease 42/37.8% n.a.
- large inflammatory bowel disease 25/22.5% n.a.
- small and large inflammatory bowel disease 44/39.6% n.a.
Digestive resections 54/48.7% n.a.
Lifetime corticosteroid dose:
none 4/4.0% n.a.
< 10 g 58/57.4% n.a.
> 10 g 39/38.6% n.a.
Corticosteroid users in 3 of the past 12 months 55/49.6% n.a.
Current corticosteroid users 37/35.7% n.a.
Current immunosuppressants (Azathioprine, 6-Mercaptopurine) 61/54.9% n.a.
Current anti-TNF users 7/6.3% n.a.
Data expressed as median with range shown in brackets. Qualitative data expressed as absolute values (n)/percentage.
Estradiol (E2) serum levels, comparing male CD patients to  healthy controls Figure 1
Estradiol (E2) serum levels, comparing male CD 
patients to healthy controls.
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There was no correlation between sex steroids and BMD,
neither in all the 111 CD patients nor in any sub-group.
￿ Biochemical markers of bone turnover and sex steroids/
bone mineral density
ICTP serum levels were increased in patients compared to
controls (3.8 μg/l vs. 3.3 μg/l; p < 0.001). Significantly
increased ICTP could be detected in the sub-group with
osteoporosis compared to patients with normal BMD (4.2
μg/l vs. 3.5 μg/l; p < 0.05). Patients with BMI < 20 kg/m2
had significant higher ICTP levels than patients with BMI
> 20 kg/m2 (table 5). In patients with higher inflamma-
tory activity, indicated by CRP levels > 5 mg/l, bone turn-
over rates were increased with higher ICTP (4.3 μg/l vs. 3.6
μg/l; p < 0.025) and osteocalcin serum levels (3.5 ng/ml
vs. 2.8 ng/ml; p < 0.05). No association between sex ster-
oid serum levels and the bone metabolism markers osteo-
calcin and ICTP was found.
Regarding the 111 male CD patients according to age at
the time of diagnosis (younger vs. older than 21 years), no
significant differences in sex steroid serum levels nor bone
mineral density were found.
Discussion
Crohn's disease (CD) is a multisystem disorder character-
ised by chronic intestinal inflammation. This disorder
often leads to reduced bone mineral density (BMD) and
osteoporosis.
To understand the role of endocrine factors CD associated
osteoporosis we investigated sex steroid serum levels,
including E2, in 111 male CD patients and 99 age-
matched male controls.
In our study, T and SHBG serum levels were decreased in
patients compared to controls (table 2). T deficiency (<
9.7 nmol/l) but normal FAI was seen in only 3/111
(2.7%) patients and 1/99 (1%) controls. No correlation
between T or SHBG and BMD or markers of bone turnover
could be found. These results suggest that T deficiency is
Table 2: Sex hormones and bone turnover markers in 111 male CD patients compared to 99 healthy controls
Patients Controls
(n = 111) (n = 99)
Median Range Median Range p
Testosterone [nmol/l] 18.2 8.8 – 48 21.4 8.7 – 39.6 *
SHBG [nmol/l] 21.0 6.9 – 69.3 33.2 6.9 – 70.5 *
FAI 87 18 – 351 65 27 – 208 **
DHT [pg/ml] 269.5 66 – 750 279.5 80 – 798 n.s.
Estradiol [pg/ml] 25.6 9.4 – 47.8 33.7 18.7 – 57.4 *
FEI 45 10 – 140 40 10 – 160 n.s.
Osteocalcin [ng/ml] 3.0 0.3 – 12.8 2.5 0.3 – 14.9 n.s.
ICTP [μg/l] 3.8 1.7 – 20.8 3.3 2.0 – 7.1 *
* p < 0,001; ** p < 0,01
Table 3: 30 male CD patients with vs. 81 male CD patients without estradiol (E2) deficiency
Estradiol < 21 pg/ml Estradiol > 24 pg/ml
(n = 30) (n = 81)
Median Range Median Range p
Age (yr) 33.0 19 – 68 38.5 19 – 71 n.s.
CDAI 176 6 – 380 88 2 – 354 **
Testosterone [nmol/l] 18.2 8.8 – 29.7 19.8 10.8 – 48.0 ***
SHBG [nmol/l] 21 7.6 – 65.6 21 6.9 – 69.3 n.s.
FAI 63 21 – 184 95 18 – 351 *
DHT [pg/ml] 179 66 – 479 297 90 – 750 ***
FEI 32 9 – 83 53 17 – 143 ****
Osteocalcin [ng/ml] 3.4 0.5 – 8.9 2.9 0.3 – 12.8 n.s.
ICTP [μg/l] 4.0 1.9 – 20.8 3.8 1.7 – 11.7 n.s.
T-score spine -2.06 -3.94 – 0.4 -1.96 -3.94 – 0.84 n.s.
* p < 0,05; ** p < 0,01; *** p < 0,001; **** p < 0,0001BMC Gastroenterology 2008, 8:48 http://www.biomedcentral.com/1471-230X/8/48
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an uncommon finding in male CD patients, confirming
data reported before [22,23,34].
Alterations of androgen (A) serum levels are believed to
play a role in male osteoporosis, but the relationship
between T serum levels and bone loss in men is less well
documented compared to E loss in postmenopausal oste-
oporosis [15,18]. Ageing otherwise healthy men lack a
distinct hormonal equivalent of the female menopause
with T serum levels not changing significantly over life
[15,18,21,35] and in the majority of cases, no overt
hypogonadism in men with osteoporosis is seen
[18,26,30,35,36]. Only the FAI, what is the serum bio-
available not SHBG bound T, decreases in elderly men
due to an age related increase in SHBG serum levels
[17,35,37,38].
Two studies reported T deficiency in 4/48 (8%) and 20/45
(44.4%) male IBD patients with 1 and 15 of them on CS
therapy, respectively [22,23]. T had no effect on bone den-
sity and metabolism [23]. Lower than normal FAI was
reported in 3/48 (6.2%) CD patients but FAI was only cal-
culated in men with low or borderline testosterone [22].
There are no data about E2 or FEI and its association to
bone loss and osteoporosis in men with CD.
Table 4: Comparing age stratified cohorts of male CD patients vs. healthy male controls
< 30 years 30 – 45 years > 45 years
Patients
(n = 32)
Controls
(n = 31)
pP a t i e n t s
(n = 48)
Controls
(n = 36)
pP a t i e n t s
(n = 31)
Controls
(n = 32)
p
Testosterone 
(nmol/l)
20.1
(8.8 – 40.6)
23.0
(11.2 – 33.9)
18.7
(9.6 – 48.0)
21.7
(10.4 – 39.6)
0.025 15.5
(11 – 26.2)
19.4
(8.7 – 32.8)
< 0.01
SHBG (nmol/l) 19,3
(6.9 – 47.3)
32
(8.2 – 46.9)
<0.0025 21.4
(11.5 – 69.3)
28.3
(6.9 – 70.5)
24.1
(12.2 – 52.7)
37.8
(12.7 – 70.4)
< 0.01
FAI 100
(34 – 100)
78
(39 – 163)
<0.025 86
(18 – 232)
65.5
(28 – 208)
67
(26 – 146)
52.5
(27 – 168)
DHT (pg/ml) 278
(66 – 562)
310
(95 – 616)
<0.05 263
(67 – 750)
266
(103 – 712)
262
(110 – 750)
218
(80 – 798)
Estradiol (pg/ml) 25.8
(12.2 – 39.6)
37.5
(29.8 – 57.4)
<0.001 24.8
(9.4 – 46.6)
32.1
(20.1 – 45.6)
<0.001 26.7
(18.4 – 47.8)
30.9
(18.7 – 52.6)
<0.0025
FEI 49
(15 – 140)
53
(25 – 136)
40
(9 – 93)
45
(15 – 158)
39
(14 – 143)
36
(11 – 96)
Osteocalcin (ng/ml) 3.4
(1.0 – 12.8)
4.5
(1.0 – 14.9)
2.8
(0.5 – 10.1)
2.4
(0.6 – 6.0)
2.6
(0.3 – 9.5)
2.1
(0.3 – 5.4)
ICTP (μg/l) 4.4
(2.1 – 11.7)
3.9
(2.0 – 7.1)
<0.05 3.6
(1.7 – 20.8)
3.1
(2.2 – 4.7)
<0.0025 3.6
(2.3 – 6.0)
3.2
(2.0 – 4.8)
<0.025
T-score
(lumbar spine)
-1.72
(-3.8 – +0.05)
-2.02
(-3.9 – +0.84)
-2.11
(-3.94 – +0.28)
Table 5: Sex hormones and bone turnover markers of 111 male CD patients divided in subgroups according to Body mass index (BMI)
AB C
BMI < 20 (n = 26) BMI 20–25 (n = 55) BMI > 25 (n = 30) p
Median Range Median Range Median Range
Testosterone (nmol/l) 19.3 8.8 – 34.4 20.4 9.5 – 48 16,95 11.1–37.1 a)
SHBG (nmol/l) 25.6 7.6 – 69.3 22.2 8.5 – 57 17,15 6.9 – 65.1 b)c)
FAI 61.5 19 – 351 90 26 – 338 93 18 – 236 n.s.
DHT (pg/ml) 256 66 – 643 270 84 – 643 275 147 – 750 n.s.
Estradiol (pg/ml) 21.6 14.1 – 41.5 25.5 9.4 – 46.6 27.1 15.3 – 47.8 d)e)
FEI 35 11 – 129 41 9 – 140 57 16 – 143 f)g)h)
Osteocalcin (ng/ml) 3.5 0.7 – 12.1 3.1 0.5 – 12.8 2.7 0.3 – 7.6 n.s.
ICTP (μg/l) 4.9 2.8 – 11.7 3,7 2.1 – 8.3 3.5 1.7 – 5.6 i)j)
lumbar T-score -2.36 -3.94 – -0.25 -2.06 -3.94–0,4 -1.56 -3.27–0.84 k)l)
Age (yr) 30.5 19 – 47 34 21 – 71 45 26 – 66 m)n)
a) p < 0,05 group B vs. C; b) p < 0,02 group A vs. C; c) p < 0,05 group B vs. C; d) p < 0,05 group A vs. B; e) p = 0,005 group A vs. C;f) p = 0,05 group A 
vs. B; g) p < 0,001 group A vs. C; h) p < 0,01 group B vs. C;i) p < 0,01 group A vs. B; j) p < 0,001 group A vs. C; k) p < 0,025 group A vs. C;l) p < 0,05 
group B vs. C.m) p < 0,001 group A vs. C.n) p < 0,01 group B vs. C.BMC Gastroenterology 2008, 8:48 http://www.biomedcentral.com/1471-230X/8/48
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In our study, E2 serum levels but not the FEI were signifi-
cantly decreased in patients. Lower than normal E2 serum
levels (< 21 pg/ml) were more present in CD patients (30/
111; 27.0%) versus controls (5/99; 5.1%). Patients with
E2 deficiency had significantly decreased T, DHT, FAI and
FEI serum levels and a higher disease activity (CDAI)
(table 3, figure 1). CS usage for at least 3 of the past 12
months had decreased E2 serum levels. However, no cor-
relation between E2 serum levels or FEI and bone density
or markers of bone turnover could be observed.
Some studies reported a closer interrelation between BMD
and estrogen compared to BMD and androgen status in
males [15,20,30]. The FEI had a higher predictive value for
BMD at all skeletal sites [34] in both, young (<50 years)
and older (>50 years) men [17,30,31,35]. E2 serum levels
were decreased but within the normal range in male idio-
pathic osteoporotic patients [30], suggesting that the
skeleton may require a certain threshold level of E to
prevent increased bone resorption and bone loss
[18,20,21,26,31]. There is little or no change in E2 serum
levels over life in men but similarly to FAI, the FEI, what
is the serum bio-available not SHBG bound E2, decreases
in elderly men due to the age related increase in SHBG
serum levels [17,21,31,38].
In CD both, reduced bone formation and increased bone
resorption is reported to play a central role in bone loss
and osteoporosis [2,4,5]. Reduced DHEAS levels in male
IBD patients were associated with higher deoxypyridino-
line excretion [23] and T was positive associated with oste-
ocalcin [22]. Therefore, estrogen deficiency is expected to
increase bone turnover rates [18,35].
Our results confirm a higher bone resorption rate in CD
patients. CD patients with osteoporosis or BMI < 20 kg/m2
revealed the highest ICTP serum levels. If the association of
decreased ICTP serum levels in CD patients with BMI > 20
kg/m2 and higher E2/FEI serum levels due to an altered E2/
FEI ratio remains unclear because we were not able to show
an association with markers of bone turnover.
The prevalence of osteoporosis (28.8%), osteopenia
(49.5%) and normal BMD (21.6%) in men with CD was
comparable to prevalence rates reported before [1,2,4-7].
A life-time steroid dose > 10 g was associated with lower
lumbar BMD, confirming former reports [3,5-7,9,12,13].
Likewise to glucocorticoids CS therapy induces a dose-
dependent increase in risk of fracture and BMD loss [12].
Patients with BMI < 20 kg/m2 had a lower lumbar BMD
compared to patients with a higher BMI, confirming pre-
vious reports that a lean body habitus seems to be a risk
factor for osteoporosis in CD patients [5,7,30,35,37].
The multiple regression model generated for BMD
explained 19% of the variance by the parameters age, BMI
and life-time steroid dose, parameters which have been
reported before [1-3,5,7]. The models R2 value suggests
that other factors may contribute significantly to BMD.
Genetic factors are reported to be most important, with up
to 60 – 80% of BMD variance being genetically deter-
mined, so only a smaller part may be determined by other
factors including hormonal status [18].
Several cross-sectional studies on idiopathic osteoporosis
in men demonstrated a closer relation between E and
BMD compared to T and BMD [17,20,30,31,36]. How-
ever, in our study, sex steroids were not significant differ-
ent in patients with osteoporosis vs. patients with
osteopenia or normal BMD, respectively (table 6). No
association of BMD to/with T, E2 or FEI serum levels was
found, neither in all patients nor in any sub-group. This
probably indicates that bone metabolism markers and sex
steroids compared to BMD taken at one time reflect differ-
ent processes in time with indices like BMD not changing
rapidly compared to humoral markers. BMD may be the
Table 6: Sex hormones and bone turnover markers of 111 male CD patients according to bone mineral density (BMD)
normal BMD Osteopenia Osteoporosis
(n = 24) (n = 55) (n = 32)
Median Range Median Range Median Range p
Age (yr) 41 19 – 67 32 19 – 63 40 19–71 n.s.
BMI (kg/m2) 25.1 19.7–34.7 23.0 16.8–29.4 22,4 16.9–30.8 *
Testosterone [nmol/l] 18.8 11.1–34.4 17.3 9.5 – 40.6 18.1 8.8 – 48 n.s.
SHBG [nmol/l] 20.6 6.9 – 57 22.2 8.5 – 69.3 18.2 7.6 – 65.6 n.s.
FAI 86.5 26 – 351 79 18 – 338 96 23 – 232 n.s.
DHT [pg/ml] 275 119 – 590 269 67 – 750 260 66 – 750 n.s.
Estradiol [pg/ml] 26.5 14.2–38.4 26.1 9.4 – 47.8 24.8 14.2–41.5 n.s.
FEI 50 10 – 130 40 10 – 140 40 10 – 111 n.s.
Osteocalcin [ng/ml] 2.6 0.7 – 10.1 2.9 0.5 – 12.8 3.3 0.3 – 12.1 n.s.
ICTP [μg/l] 3.5 1.9 – 20.8 3.7 1.7 – 11.6 4.2 2.7 – 11.7 *
* p < 0,05 comparing patients with normal BMD to patients with osteoporosisBMC Gastroenterology 2008, 8:48 http://www.biomedcentral.com/1471-230X/8/48
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cumulative result of different processes taking place ear-
lier and over a longer period of time. Only data of a fol-
low-up study relating rates of change in BMD to serum sex
steroids levels would prove the effect of E and T deficiency
on bone loss and osteoporosis as confounding factor
associating BMD and sex steroids also in men with CD.
Conclusion
Our results show that male CD patients have decreased E2
and, to a lesser extent T serum levels with nearly one-third
of male CD patients having E2 serum levels below the
normal range. We could not consider low E2 levels as a
surrogate marker for glucocorticoid treatment or disease
activity in general, even with regard to the results that
male CD patients with higher disease activity, according
to CDAI, or CS users had decreased E2/FEI and T serum
levels. Overall our data emphasize the fact that an optimal
control of inflammation in CD patients is crucial.
We failed to show a direct interrelation between the
altered hormonal status and bone density and metabo-
lism, confirming results in primary male osteoporosis,
where E2 deficiency in 14/42 (33%) men did not correlate
with BMD [26]. The role of E2 in the negative skeletal bal-
ance in males with CD, analogous to E2 deficiency in
postmenopausal females, deserves further attention.
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